Journal
TRENDS IN CELL BIOLOGY
Volume 22, Issue 4, Pages 211-219Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tcb.2011.11.006
Keywords
senescence; cancer; therapy; tumor suppressors; secretome; p53; Myc; Ras
Categories
Funding
- MRC Technology
- Cancer Research UK
- Association for International Cancer Research
- EMBO
- Medical Research Council (MRC)
- MRC [MC_U120085810] Funding Source: UKRI
- Medical Research Council [MC_U120085810] Funding Source: researchfish
Ask authors/readers for more resources
Senescence is a stable cell cycle arrest that can be activated by oncogenic signaling and manifests with changes in cellular organization and gene expression, such as the induction of a complex secretome. Importantly, senescence limits tumor progression and determines the outcome of conventional anticancer therapies. In recent years, therapeutic approaches such as p53 reactivation, inhibition of c-MYC in addicted tumors or treatment with cyclin-dependent kinase (CDK) inhibitors have proven effective by invoking a senescence response. The possibility of using prosenescence therapies for cancer treatment has provoked considerable interest. We propose that the senescence secretome can be a source of novel targets for prosenescence therapies, as it has tumor suppressive actions. Overall, tailored prosenescence therapies have the potential to be used for treating cancer and other pathologies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available